Article Details

Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Chardan Capital

Retrieved on: 2019-05-18 02:43:33

Tags for this article:

Click the tags to see associated articles and topics

Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Chardan Capital. View article details on hiswai:

Excerpt

<div>Finally, <b>Two Sigma Investments</b> LP acquired a new stake in Seres Therapeutics in the 4th quarter valued at about $82,000. 79.81% of the stock is ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo